

- human breast cancer: specific immune reactivity detected by measuring cytokine secretion. *J. Immunother.* **12**, 1–12 (1992).
78. Itoh, K., Tilden, A. B., & Balch, C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. *Cancer Res.* **46**, 3011–3017 (1986).
79. Topalian, S. L., Solomon, D., & Rosenberg, S. A. Tumor-specific cytotoxicity by lymphocytes infiltrating human melanomas. *J. Immunol.* **142**, 3714–3725 (1989).
80. Yannelli, J. R. *et al.* Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. *Int. J. Cancer* **65**, 413–421 (1996).
81. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. *J. Immunother.* **26**, 332–342 (2003).
82. Rosenberg, S. A. *et al.* Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. *J. Natl Cancer Inst.* **86**, 1159–1166 (1994).
- A comprehensive summary of the clinical experience with TIL for the treatment of patients with melanoma in the absence of non-myeloablative conditioning.**
83. Rosenberg, S. A. *et al.* Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N. Engl. J. Med.* **323**, 570–578 (1990).
84. Maine, G. N. & Mule, J. J. Making room for T cells. *J. Clin. Invest.* **110**, 157–159 (2002).
85. Fry, T. J. & Mackall, C. L. Interleukin-7: master regulator of peripheral T-cell homeostasis? *Trends. Immunol.* **22**, 564–571 (2001).
86. Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E. & Rosenberg, S. A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. *J. Clin. Oncol.* **19**, 3477–3482 (2001).
87. Yee, C. *et al.* Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo. *J. Exp. Med.* **192**, 1637–1644 (2000).
88. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J. Exp. Med.* **190**, 355–366 (1999).
89. Overwijk, W. W. *et al.* Vaccination with a recombinant vaccinia virus encoding a ‘self’ antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. *Proc. Natl Acad. Sci. USA* **96**, 2982–2987 (1999).
90. Phan, G. Q. *et al.* Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc. Natl Acad. Sci. USA* **100**, 8372–8377 (2003).
91. Clay, T. M. *et al.* Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. *J. Immunol.* **163**, 507–513 (1999).
92. Hwu, P. *et al.* *In vivo* antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. *Cancer Res.* **55**, 3369–3373 (1995).
93. Wherry, E. J. *et al.* Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nature Immunol.* **4**, 225–234 (2003).
94. Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8<sup>+</sup> memory T-cell subsets in response to antigen or homeostatic cytokines. *Blood* **101**, 4260–4266 (2003).
95. Liu, K. & Rosenberg, S. A. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. *J. Immunol.* **167**, 6356–6365 (2001).
96. Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science* **300**, 339–342 (2003).
97. Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* **300**, 337–339 (2003).

 Online links

## DATABASES

**Cancer.gov:** <http://cancer.gov/melanoma>

**LocusLink:** <http://www.ncbi.nlm.nih.gov/LocusLink/beta-catenin> | CD4 | CD8 | CD25 | CTLA-4 | FASL | gp100 | HLA-A2 | IFN- $\gamma$  | IL-2 | MART-1 | NY-ESO-1 | TRAIL | tumour-necrosis factor- $\alpha$

The following terms in this article are linked online to:

## FURTHER INFORMATION

**Steven A. Rosenberg's lab:**

<http://ccr.cancer.gov/Staff/Staff.asp?StaffID=615>

Access to this interactive links box is free online.